Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + Tislelizumab vs Durvalumab in Stage III NSCLC (AdvanTIG-301)
NCT04866017Phase 3Terminated
- Sponsor
- BeiGene
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
- Countries
- 5
01
Overview
A Phase 3 trial of ociperlimab in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Jun 2021; status: terminated.
02
Drugs
ociperlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04866017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04866017.